Analysts Set Xencor, Inc. (NASDAQ:XNCR) Price Target at $24.38

Shares of Xencor, Inc. (NASDAQ:XNCR) have received an average rating of “Moderate Buy” from the ten ratings firms that are presently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and seven have issued a buy recommendation on the company. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is $24.3750.

A number of analysts recently commented on XNCR shares. Wall Street Zen lowered Xencor from a “hold” rating to a “sell” rating in a report on Saturday, February 28th. Barclays raised their price target on shares of Xencor from $26.00 to $27.00 and gave the stock an “overweight” rating in a research note on Thursday, February 26th. Weiss Ratings restated a “sell (d-)” rating on shares of Xencor in a research note on Friday, March 27th. Finally, JPMorgan Chase & Co. restated a “neutral” rating and issued a $13.00 target price (down from $18.00) on shares of Xencor in a research note on Tuesday, March 24th.

Insider Buying and Selling at Xencor

In other Xencor news, SVP Celia Eckert sold 3,244 shares of the business’s stock in a transaction on Thursday, March 5th. The stock was sold at an average price of $11.25, for a total value of $36,495.00. Following the sale, the senior vice president directly owned 78,685 shares in the company, valued at $885,206.25. The trade was a 3.96% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Bassil I. Dahiyat sold 6,606 shares of the business’s stock in a transaction on Friday, March 6th. The shares were sold at an average price of $11.02, for a total value of $72,798.12. Following the completion of the sale, the chief executive officer owned 546,316 shares in the company, valued at approximately $6,020,402.32. The trade was a 1.19% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 44,020 shares of company stock worth $499,817 over the last ninety days. 4.76% of the stock is currently owned by company insiders.

Institutional Trading of Xencor

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Seven Fleet Capital Management LP bought a new stake in shares of Xencor during the 4th quarter valued at $1,677,000. Invesco Ltd. raised its stake in shares of Xencor by 5.7% during the 4th quarter. Invesco Ltd. now owns 265,820 shares of the biopharmaceutical company’s stock valued at $4,070,000 after purchasing an additional 14,216 shares during the period. EP Wealth Advisors LLC bought a new stake in shares of Xencor during the 4th quarter valued at $202,000. XTX Topco Ltd bought a new stake in shares of Xencor during the 4th quarter valued at $490,000. Finally, Voloridge Investment Management LLC bought a new stake in shares of Xencor during the 4th quarter valued at $1,343,000.

Xencor Stock Down 2.9%

Shares of NASDAQ:XNCR opened at $12.44 on Friday. The stock has a market cap of $912.35 million, a price-to-earnings ratio of -10.03 and a beta of 0.99. The company has a quick ratio of 6.25, a current ratio of 6.25 and a debt-to-equity ratio of 0.12. Xencor has a 12-month low of $6.92 and a 12-month high of $18.69. The business’s 50 day moving average is $12.00 and its 200 day moving average is $13.54.

Xencor (NASDAQ:XNCR) last announced its earnings results on Wednesday, February 25th. The biopharmaceutical company reported ($0.09) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.64) by $0.55. The company had revenue of $28.24 million for the quarter, compared to analysts’ expectations of $29.97 million. Xencor had a negative return on equity of 14.58% and a negative net margin of 73.20%.Xencor’s quarterly revenue was down 46.6% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.62) earnings per share. On average, sell-side analysts forecast that Xencor will post -3.68 earnings per share for the current fiscal year.

About Xencor

Xencor, Inc is a clinical-stage biopharmaceutical company focused on the design and development of engineered protein therapeutics for the treatment of autoimmune diseases, cancer and neurological disorders. The company applies its proprietary XmAb® platform to manipulate antibody structure and function, creating molecules with enhanced immune engagement and extended half-life. Xencor’s research programs span a range of therapeutic modalities, including monoclonal antibodies, bispecific antibodies and cytokine-based fusion proteins.

The XmAb® platform enables precise modification of the Fc region to augment key properties such as receptor binding, effector function and pharmacokinetics.